<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology and clinical manifestations of Cushing syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology and clinical manifestations of Cushing syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology and clinical manifestations of Cushing syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The symptoms and signs of Cushing syndrome result directly from chronic exposure to excess glucocorticoid. Establishing the diagnosis is often difficult because few of the symptoms or signs are pathognomonic of the syndrome in isolation. There is a large spectrum of manifestations from subclinical to overt syndrome, depending on duration and intensity of excess steroid production. Furthermore, some of them (such as obesity, hypertension, and glucose intolerance) are common in individuals who do not have adrenal hyperfunction. An important clinical clue to the presence of glucocorticoid excess is the <strong>simultaneous development and increasing severity</strong> of several of these symptoms.</p><p>The major manifestations of Cushing syndrome will be reviewed here. The diagnosis and treatment of this disorder and Cushing syndrome during pregnancy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/139.html" rel="external">"Diagnosis and management of Cushing syndrome during pregnancy"</a>.)</p><p class="headingAnchor" id="H588675336"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Estimates of the incidence of Cushing syndrome are imprecise and likely underestimate the incidence of iatrogenic Cushing syndrome, undiagnosed mild hypercortisolism, and the ectopic corticotropin (ACTH) syndrome.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iatrogenic Cushing syndrome</strong> – More than 10 million Americans receive pharmacologic doses of glucocorticoids each year. Therefore, iatrogenic Cushing syndrome must be more common than any other cause but is seldom reported. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Dermatologic effects and appearance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cushing disease</strong> – Pituitary ACTH-dependent Cushing causes 65 to 70 percent of Cushing syndrome [<a href="#rid1">1</a>]. The reported incidence was 1.2 to 2.4 per million per year in European population-based studies [<a href="#rid2">2,3</a>] and 6.2 to 7.6 per million person-years in the United States [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome", section on 'Cushing disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ectopic ACTH syndrome</strong> – Recognized ectopic ACTH syndrome causes 10 to 15 percent of cases. However, its true incidence is probably more common because a number of these patients do not present with catabolic features and are not diagnosed. For example, small cell lung cancer is diagnosed in approximately 8 of 100,000 persons annually, in whom the ectopic ACTH syndrome is diagnosed in approximately 1 percent, approximately 1 per million [<a href="#rid5">5,6</a>]. As ectopic ACTH secretion accounts for only approximately 15 percent of Cushing syndrome, it is clear that it is underdiagnosed. Other causes of ectopic ACTH syndrome, such as pulmonary neuroendocrine tumors, are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome", section on 'Ectopic ACTH syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenal tumors</strong> – Adrenal carcinoma and adenoma cause a similar number of cases of Cushing syndrome in most series, together comprising approximately 20 percent of all cases. However, a preponderance of Cushing syndrome caused by adrenal adenomas has been described in Hokkaido, Japan and in Italy [<a href="#rid7">7,8</a>]. Based on the United States Surveillance, Epidemiology, and End Result (SEER) database, the incidence of adrenal carcinoma from 2000 to 2012 was estimated to be 1.26 per million per year [<a href="#rid9">9</a>]. A population-based study in Denmark reported the incidence of adrenal adenoma and adrenal carcinoma as 0.6 and 0.2 per million per year, respectively [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All <strong>other causes</strong> of Cushing syndrome are extremely rare, including Cushing syndrome due to either bilateral macronodular adrenal hyperplasia or primary pigmented nodular adrenocortical disease, which are discussed elsewhere. Ectopic production of corticotropin-releasing hormone (CRH) is perhaps the most uncommon cause of the syndrome. (See  <a class="medical medical_review" href="/z/d/html/148.html" rel="external">"Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia"</a> and  <a class="medical medical_review" href="/z/d/html/152.html" rel="external">"Cushing syndrome due to primary pigmented nodular adrenocortical disease"</a>.)</p><p></p><p>The incidence of Cushing syndrome varies by both sex and age. The <strong>sex-related</strong> distribution of Cushing syndrome varies with the cause:</p><p class="bulletIndent1"><span class="glyph">●</span>Males had a three times greater incidence of the ectopic ACTH syndrome 30 years ago, but the increasing incidence of lung cancer in cigarette-smoking females has narrowed that margin. (See  <a class="medical medical_review" href="/z/d/html/4628.html" rel="external">"Pathobiology and staging of small cell carcinoma of the lung", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females are three to eight times more likely than males to develop Cushing disease [<a href="#rid1">1</a>], approximately three times more likely to have either benign or malignant adrenal tumors, and approximately four to five times more likely to have Cushing syndrome associated with an adrenal tumor [<a href="#rid1">1,10-12</a>]. The reasons for this preponderance in females are unknown.</p><p></p><p>The <strong>age</strong> at presentation varies depending upon the cause of hypercortisolism:</p><p class="bulletIndent1"><span class="glyph">●</span>The age at which the ectopic ACTH syndrome develops parallels the development of lung carcinoma, increasing rapidly after age 50 years. Ectopic ACTH secretion due to more benign neuroendocrine tumors (previously termed carcinoids) can occur at earlier ages but is rare in children [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/4628.html" rel="external">"Pathobiology and staging of small cell carcinoma of the lung", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cushing disease occurs mainly in women aged 25 to 45 years. It is unusual in children but still accounts for most cases of childhood Cushing syndrome [<a href="#rid13">13-15</a>]. In two small studies reporting on approximately 20 prepubertal children, boys were affected more often than girls (18:2), while 36 of 53 adolescents with Cushing disease were female [<a href="#rid14">14,16-18</a>]. (See  <a class="medical medical_review" href="/z/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome", section on 'Cushing disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal tumors have a bimodal age distribution, with small peaks in the first decade of life for both adenomas and carcinomas and major peaks at approximately 50 years for adenomas and 40 years for carcinomas [<a href="#rid11">11,19</a>]. One literature review found that adrenal tumors (benign and malignant) cause 41 percent of all cases of childhood Cushing syndrome, with primary pigmented nodular dysplasia accounting for approximately 6 percent [<a href="#rid15">15</a>]. Girls are affected slightly more often than boys. (See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">FREQUENCY AND SEVERITY OF SYMPTOMS</span></p><p class="headingAnchor" id="H28079343"><span class="h2">Most common symptoms</span><span class="headingEndMark"> — </span>The major symptoms and signs of Cushing syndrome are listed in the table  (<a class="graphic graphic_table graphicRef111525" href="/z/d/graphic/111525.html" rel="external">table 1</a>) and reviewed in detail in this section [<a href="#rid20">20-22</a>].</p><p>In adults, signs and symptoms most suggestive of the presence of hypercortisolism include proximal muscle weakness, facial plethora, wasting of the extremities with increased fat in the abdomen and face, wide purplish striae, bruising with no obvious trauma, and supraclavicular fat pads [<a href="#rid23">23-25</a>]. An important clinical clue to the presence of glucocorticoid excess is the simultaneous development or accumulation of new features over time and increasing severity of several of these symptoms.</p><p>The clinical manifestations of Cushing syndrome can be categorized as reproductive, dermatologic, metabolic, cardiovascular, musculoskeletal, neuropsychiatric, and infectious. In addition to the considerable morbidity caused by hypercortisolism, there is also an increase in mortality rates  (<a class="graphic graphic_table graphicRef111525" href="/z/d/graphic/111525.html" rel="external">table 1</a>). (See <a class="local">'Mortality'</a> below.)</p><p class="headingAnchor" id="H2957505699"><span class="h2">Severity of symptoms</span><span class="headingEndMark"> — </span>When hypercortisolism is severe, its signs and symptoms are unmistakable. However, many of the signs and symptoms of Cushing syndrome can occur in individuals without hypercortisolism, and not all patients with Cushing syndrome present with obvious features.</p><p>The presence and relative severity of symptoms varies, being determined by the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>The degree and duration of hypercortisolism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence or absence of androgen excess (because hypercortisolism alone causes neither hirsutism nor pustular acne).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cause of the hypercortisolism (because hyperpigmentation is caused by increased secretion of corticotropin [ACTH]) and androgen excess occurs only in females with adrenal cancer or ACTH-stimulated hyperandrogenism (the adrenal gland being a major source of androgen production in females but not males). Adrenal adenomas generally secrete only glucocorticoids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal carcinoma or the ectopic ACTH syndrome can cause tumor-related symptoms that may overshadow the effects of hypercortisolism (such as weight loss instead of weight gain).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with adrenal adenomas, both the degree of hypercortisolemia and many of the clinical manifestations of Cushing syndrome tend to be less severe in patients &gt;50 years of age [<a href="#rid21">21</a>]. Many patients with incidentally discovered adrenal adenomas have subclinical Cushing syndrome (mild hypercortisolism without clinical manifestations of Cushing syndrome, now often referred to as "autonomous cortisol secretion"), but glucose intolerance and hypertension are common [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H1059123486"><span class="h1">CATEGORIES OF CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H862321039"><span class="h2">Reproductive</span></p><p class="headingAnchor" id="H3994822162"><span class="h3">Menstrual irregularities</span><span class="headingEndMark"> — </span>Menstrual irregularities are common in women with Cushing syndrome. In one series of 45 women with newly diagnosed Cushing disease, 80 percent had abnormal menstrual cycles, 31 percent had oligomenorrhea, 33 percent had amenorrhea, and the remainder had excess or variable menses [<a href="#rid26">26</a>]. The menstrual abnormalities correlated with increased serum cortisol and decreased serum estradiol concentrations but not with serum androgen concentrations. Because both luteinizing hormone and follicle-stimulating hormone levels are low, the menstrual irregularities appear to be due to suppression of secretion of gonadotropin-releasing hormone by hypercortisolemia [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H2129279981"><span class="h3">Signs of adrenal androgen excess</span><span class="headingEndMark"> — </span>Females with some types of Cushing syndrome (most commonly adrenal carcinoma) have signs of androgen excess [<a href="#rid28">28</a>]. The adrenal glands are the major source of androgens in females [<a href="#rid29">29</a>]. In contrast, the testes are the major source of androgens in males [<a href="#rid30">30</a>]. Thus, males with Cushing syndrome do not have signs of androgen excess, because cortisol has no androgenic activity [<a href="#rid31">31</a>].</p><p>Signs of androgen excess in Cushing syndrome are most common in women with adrenal carcinomas [<a href="#rid10">10,19</a>]. These tumors usually secrete large amounts of androgenic precursors because they are inefficient at converting cholesterol to cortisol [<a href="#rid32">32,33</a>]. In comparison, signs of androgen excess are usually mild in women with ACTH-dependent Cushing syndrome and do not occur in women with adrenal adenomas [<a href="#rid19">19</a>].</p><p>Androgen excess in affected women can cause the following symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Hirsutism, which is usually mild and limited to the face but can be generalized. Downy sideburns and increased hair on the upper lip and under the chin are most common  (<a class="graphic graphic_picture graphicRef77261" href="/z/d/graphic/77261.html" rel="external">picture 1</a>). The scalp hair often becomes thin, but temporal balding is rare.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oily facial skin and acne on the face, neck, or shoulders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased libido (however, decreased libido is more common, occurring in 70 percent of patients in one series [<a href="#rid34">34</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Virilization, including temporal balding, deepening voice, male body habitus, male escutcheon, and clitoral hypertrophy, occurs only in girls or women with extremely high serum concentrations of androgens due to an adrenal carcinoma. Prepubertal males may develop premature puberty<strong> </strong> (<a class="graphic graphic_picture graphicRef55622" href="/z/d/graphic/55622.html" rel="external">picture 2</a>).</p><p></p><p class="headingAnchor" id="H1128747132"><span class="h2">Dermatologic</span><span class="headingEndMark"> — </span>Many changes in the skin and subcutaneous tissue occur in patients with Cushing syndrome. Unlike most other symptoms and signs associated with Cushing syndrome, which can occur alone or in combination in normal subjects and patients with pseudo-Cushing states, the dermatologic changes characteristic of Cushing syndrome seldom occur in other subjects [<a href="#rid23">23,35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Easy bruisability</strong> – Loss of subcutaneous connective tissue due to the catabolic effects of glucocorticoid results in easy bruising after minimal, often unremembered, injury<strong> </strong> (<a class="graphic graphic_picture graphicRef65564" href="/z/d/graphic/65564.html" rel="external">picture 3</a>). Extensive ecchymoses at venipuncture sites are also common, and it is often difficult to maintain intravenous lines without fluid infiltration into the surrounding tissues. As a result, patients with Cushing syndrome are sometimes thought to have senile purpura or a bleeding diathesis [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Striae</strong> – Purple striae occur as the fragile skin stretches due to the enlarging trunk, breasts, and abdomen  (<a class="graphic graphic_picture graphicRef67682" href="/z/d/graphic/67682.html" rel="external">picture 4</a>). The striae appear as wide, reddish-purple streaks because the increasingly thin skin does not hide the color of venous blood in the underlying dermis. Striae occur most often in younger patients, can be numerous, and are most common on the abdomen and lower flanks; however, they can also occur on the breasts, hips, buttocks, shoulders, upper thighs, upper arms, and axillae [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin atrophy</strong> – The skin usually atrophies, the stratum corneum is thinned, and there is loss of subcutaneous fat to a sufficient degree that subcutaneous blood vessels may be seen [<a href="#rid38">38</a>]. The skin eventually becomes fragile due to these changes and, in extreme cases, peels off after being covered with adhesive tape. Minor wounds heal slowly, and surgical wounds may dehisce. Such changes should be considered in the context of sex and age differences in skin thickness, with healthy men and younger individuals having greater skin thickness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fungal infections</strong> – Cutaneous fungal infections, especially tinea versicolor, are often found on the trunk. Some patients have fungal infections of the nails, but oral candidiasis is rare.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperpigmentation</strong> – Hyperpigmentation is induced by increased ACTH, not cortisol, secretion. ACTH is the principal pigmentary hormone in humans. It acts via binding to melanocyte-stimulating hormone receptors [<a href="#rid39">39</a>]. The degree of hyperpigmentation is dependent upon both the duration and the degree of increase in ACTH secretion.</p><p></p><p class="bulletIndent1">Hyperpigmentation occurs most often in patients with the ectopic ACTH syndrome, less often in those with pituitary overproduction of ACTH, and not at all in patients with adrenal tumors in whom ACTH secretion is suppressed.</p><p></p><p class="bulletIndent1">Hyperpigmentation may be generalized but is most conspicuous in areas exposed to light (such as the face, neck, and back of the hands) or to chronic mild trauma, friction, or pressure (such as the elbows, knees, spine, knuckles, waist [belt], midriff [girdle], and shoulders [brassiere straps])  (<a class="graphic graphic_picture graphicRef70693 graphicRef61260" href="/z/d/graphic/70693.html" rel="external">picture 5A-B</a>). Patchy pigmentation may occur on the inner surface of lips and the buccal mucosa along the line of dental occlusion<strong> </strong> (<a class="graphic graphic_picture graphicRef56401" href="/z/d/graphic/56401.html" rel="external">picture 6</a>). The hyperpigmentation is less pronounced than in patients with chronic primary adrenal insufficiency.</p><p></p><p class="bulletIndent1">Acanthosis nigricans also can be present in the axillae and around the neck.</p><p></p><p class="bulletIndent1">Surgical or traumatic scars that form when plasma ACTH concentrations are markedly elevated are permanently pigmented. In comparison, scars incurred before ACTH hypersecretion or after it is reduced are not pigmented.</p><p></p><p class="headingAnchor" id="H3083926909"><span class="h2">Metabolic</span></p><p class="headingAnchor" id="H3998129710"><span class="h3">Glucose intolerance</span><span class="headingEndMark"> — </span>Glucose intolerance is common in Cushing syndrome. It is primarily due to stimulation of gluconeogenesis by cortisol and peripheral insulin resistance caused by obesity, but direct suppression of insulin release also may contribute. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>Overt hyperglycemia occurs in only 10 to 15 percent of patients, usually those with a family history of type 2 diabetes mellitus [<a href="#rid40">40</a>]. Diabetic ketoacidosis is rare and, if present, usually indicates unsuspected type 1 diabetes exacerbated by hypercortisolemia.</p><p>Poorly controlled hyperglycemia in a person with obesity may be a clue to the presence of Cushing syndrome. One report, for example, found that 3 percent of such patients had Cushing syndrome [<a href="#rid41">41</a>]. In a prospective study of 200 individuals with obesity, type 2 diabetes, and no symptoms of Cushing syndrome, four patients (2 percent) were identified as having occult Cushing syndrome (three with Cushing disease and one with an adrenal adenoma) [<a href="#rid42">42</a>]. However, a subsequent study of 201 patients did not identify any with Cushing syndrome [<a href="#rid43">43</a>]. Thus, it is not recommended to screen patients with diabetes unless they have other features of the disorder [<a href="#rid24">24</a>].</p><p>Patients with Cushing syndrome who have hyperglycemia should be treated like any other patient with type 2 diabetes (see  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a>). The hyperglycemia becomes much easier to control and may completely remit if the hypercortisolism is reversed [<a href="#rid44">44</a>].</p><p>Increased urinary albumin excretion appears to be common in Cushing syndrome, and it is reversible. In a study of 13 patients, 80 percent had increased urinary albumin excretion, but neither the presence nor the degree of albuminuria was correlated with blood pressure or fasting plasma glucose concentrations [<a href="#rid45">45</a>]. Kidney biopsies in three patients with microalbuminuria showed normal glomeruli with no evidence of diabetic or hypertensive nephropathy.</p><p class="headingAnchor" id="H3724384877"><span class="h3">Progressive obesity</span><span class="headingEndMark"> — </span>The most common feature of patients with Cushing syndrome is progressive, central (centripetal) obesity<strong> </strong> (<a class="graphic graphic_picture graphicRef82114" href="/z/d/graphic/82114.html" rel="external">picture 7</a>), usually involving the face, neck, trunk, abdomen<strong> </strong> (<a class="graphic graphic_picture graphicRef50564" href="/z/d/graphic/50564.html" rel="external">picture 8</a>), and, internally, spinal canal and mediastinum [<a href="#rid46">46,47</a>]. The extremities are often spared and may be wasted. Some authors report generalized obesity in a majority of adults with Cushing syndrome [<a href="#rid23">23</a>].</p><p>Children with Cushing syndrome almost invariably have generalized obesity and growth retardation; the latter may be the first indication of glucocorticoid excess. As a result, any child whose weight rises and height falls in percentile rank as compared with age-matched normal children should be considered to have Cushing syndrome until proven otherwise  (<a class="graphic graphic_figure graphicRef87007" href="/z/d/graphic/87007.html" rel="external">figure 1</a>). These abnormalities both improve after successful treatment of patients whose bones have not yet fused [<a href="#rid48">48</a>].</p><p>Fat can also accumulate in the following areas in patients with Cushing syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span>Fat accumulation in the cheeks and the temporal fossae results in a "moon" face that sometimes obscures the ears when a patient is examined from the front  (<a class="graphic graphic_picture graphicRef77261" href="/z/d/graphic/77261.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A "buffalo hump" or dorsocervical fat pad is common and is usually consistent with the general degree of obesity  (<a class="graphic graphic_picture graphicRef82478" href="/z/d/graphic/82478.html" rel="external">picture 9</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enlarged fat pads that fill the supraclavicular fossae and obscure the clavicles are one of the most specific signs of Cushing syndrome [<a href="#rid23">23</a>], although they occasionally occur in exogenous obesity. The bulging, supraclavicular fat pads make the neck appear thick and shortened  (<a class="graphic graphic_picture graphicRef77261" href="/z/d/graphic/77261.html" rel="external">picture 1</a>). Retroorbital fat deposition may result in exophthalmos, which is present in up to 5 percent of patients [<a href="#rid49">49,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, fat accumulation in the epidural space leads to neurologic abnormalities, usually in patients with ectopic ACTH secretion or exogenous steroid administration [<a href="#rid51">51</a>].</p><p></p><p>The degree of fat accumulation in Cushing syndrome is variable. Patients who diet and exercise rigorously may have little or no weight gain, facial rounding, or central weight redistribution. Other patients with no weight gain still have central weight redistribution. The cause of abdominal fat may be caused by cortisol-induced downregulation of adenosine monophosphate-activated protein kinase (AMPK), which regulates lipid and carbohydrate metabolism [<a href="#rid52">52</a>].</p><p>The conversion of cortisone to cortisol also contributes to fat deposition, as shown by a report of the absence of abnormal fat accumulation in a patient with a mutation that prevented this conversion [<a href="#rid53">53</a>].</p><p>Patients with Cushing syndrome have higher serum leptin concentrations than subjects with obesity and a similar body mass index (BMI) [<a href="#rid54">54</a>]. Leptin secretion does not respond to changes in plasma ACTH or serum cortisol concentrations, but it does appear to vary according to changes in fat mass and peripheral insulin resistance (and therefore serum insulin concentrations), as it does in other subjects with obesity [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H1011111956"><span class="h3">Sleep apnea</span><span class="headingEndMark"> — </span>In one study, sleep apnea was diagnosed in 10 of 22 patients with Cushing disease or adrenal adenoma [<a href="#rid56">56</a>]. In the same study, patients without sleep apnea showed abnormal sleep architecture and fragmented sleep with shortened rapid eye movement latency, similar to that seen in depression [<a href="#rid56">56</a>]. These abnormalities may contribute to the fatigue that is common in these patients [<a href="#rid34">34</a>].</p><p>It is likely that central obesity and possibly myopathy of the muscles that maintain airway patency both contribute to the development of sleep apnea [<a href="#rid57">57</a>]. There are no data regarding reversal after cure of Cushing syndrome.</p><p class="headingAnchor" id="H2070761869"><span class="h2">Cardiovascular</span><span class="headingEndMark"> — </span>Patients with endogenous Cushing syndrome are at increased risk of death from cardiovascular disease, including myocardial infarction, stroke, and thromboembolism [<a href="#rid2">2,3,58</a>]. (See <a class="local">'Thromboembolic events'</a> below.)</p><p>Other common cardiovascular problems in patients with Cushing syndrome include hypertension and dyslipidemia. In addition, a study of 15 patients with ACTH-dependent Cushing syndrome reported an increase in markers of subclinical atherosclerosis (coronary calcifications and noncalcified plaque volumes) when compared with controls [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H135838984"><span class="h3">Cardiovascular risk</span><span class="headingEndMark"> — </span>One study estimated cardiovascular risk in 49 patients with active Cushing syndrome according to World Health Organization (WHO)/International Society of Hypertension (ISH) criteria. Eighty percent of patients had a high or very high risk: 85 percent had hypertension, 47 percent had diabetes, and 41 percent had obesity [<a href="#rid59">59</a>]. Thus, aggressive treatment of these factors is warranted.</p><p>Although markers of cardiovascular risk, including lipid profiles, waist-to-hip ratios, and carotid artery intima medial thickness, improve in patients cured of their Cushing disease, they may not normalize, suggesting that cured patients continue to have excess cardiovascular risk (possibly due to residual abdominal obesity and/or insulin resistance) [<a href="#rid60">60,61</a>].</p><p>Patients with subclinical Cushing syndrome due to an adrenal incidentaloma may also have excess cardiovascular risk [<a href="#rid62">62-64</a>]. (See  <a class="medical medical_review" href="/z/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'</a>.)</p><p class="headingAnchor" id="H225733108"><span class="h3">Hypertension</span><span class="headingEndMark"> — </span>The pathogenesis of hypertension in Cushing syndrome is multifactorial and not fully understood; however, the following factors may be important [<a href="#rid65">65,66</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased peripheral vascular sensitivity to adrenergic agonists [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased hepatic production of renin substrate (angiotensinogen); based on this observation, one consensus paper suggests that angiotensin-converting enzyme (ACE) inhibitors should be considered the first-line treatment of hypertension in patients with Cushing syndrome [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activation of renal tubular type 1 (mineralocorticoid) receptors by cortisol (this mechanism applies mainly to patients with severe hypercortisolism, which is usually due to ectopic ACTH secretion) [<a href="#rid69">69,70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is also possible that cortisol has a direct cardiotoxic effect [<a href="#rid71">71</a>].</p><p></p><p>Treatment of hypertension in patients with Cushing syndrome does not differ from that of patients with primary hypertension (formerly called "essential" hypertension). However, blocking mineralocorticoid activity with <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> may be particularly effective in patients with very high serum cortisol concentrations, especially those with hypokalemia. The hypertension usually becomes easier to control and may entirely disappear when the Cushing syndrome is treated [<a href="#rid72">72</a>].</p><p>Severe hypertension and hypokalemia are more prevalent in patients with ectopic ACTH [<a href="#rid73">73</a>]. The high serum cortisol concentrations overwhelm the ability of the kidneys to convert cortisol to cortisone, resulting in activation of mineralocorticoid receptors as described above. Hypokalemia may also result from adrenal hypersecretion of mineralocorticoids, such as deoxycorticosterone and corticosterone [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/z/d/html/2346.html" rel="external">"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)", section on 'Ectopic ACTH syndrome'</a>.)</p><p class="headingAnchor" id="H2088799761"><span class="h3">Thromboembolic events</span><span class="headingEndMark"> — </span>An increase in venous thromboembolism (VTE) risk has been reported in most studies of patients with Cushing syndrome [<a href="#rid23">23,75-78</a>]. In a systematic review of 15 studies, the risk of postoperative VTE ranged from 0 to 5.6 percent (with one outlier of 20 percent) [<a href="#rid79">79</a>]. In two of the studies, the risk of VTE not related to surgery was reported to be 1.9 and 2.5 percent. Based upon the 6 to 9.7 years of follow-up in these studies, this corresponded to an incidence of 2.5 to 3.1 per 1000 person-years [<a href="#rid79">79</a>], much higher than the estimated incidence in an age- and sex-matched population (VTE incidence for 40-year-old women = 0.3 per 1000 person-years) [<a href="#rid80">80</a>].</p><p>In a multicenter cohort study of patients with Cushing syndrome published after the systematic review (n = 473; 360 with ACTH-dependent pituitary Cushing syndrome, 113 with ACTH-independent adrenal disease), VTE rates not related to surgery were higher than reported in the systematic review, while postoperative rates were in a similar range [<a href="#rid81">81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior to treatment, 17 patients with Cushing syndrome (4 percent) had a VTE, for an incidence rate of 12.9 per 1000 person-years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The frequency of postoperative VTE (within three months after transsphenoidal surgery for ACTH dependent or adrenalectomy for ACTH independent) was 3.4 and 0 percent, respectively [<a href="#rid81">81</a>]. The 3.4 percent postoperative risk in those with ACTH-dependent disease (12 events in 350 patients) translates to an incidence of 141 per 1000 person-years. No episodes of postoperative VTE were seen in a control group of 185 patients undergoing pituitary surgery for nonfunctioning adenomas.</p><p></p><p>The risk is possibly due to glucocorticoid-induced increases in plasma concentrations of clotting factors, especially factor VIII and von Willebrand factor complex, and decreases in fibrinolytic activity [<a href="#rid75">75-77</a>]. Elevated serum homocysteine concentrations, which appear to be associated with an increased risk of cardiovascular disease and venous thrombosis, have been reported in patients with Cushing syndrome [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/z/d/html/6837.html" rel="external">"Overview of homocysteine"</a>.)</p><p>Clinical features that appear to contribute to the excess risk of thromboembolism include obesity and surgery [<a href="#rid79">79</a>]. Another study that examined factors in 20 of 176 patients who developed venous thromboembolism found risk factors of age ≥69 years, reduced mobility, acute severe infections, previous cardiovascular events, midnight plasma cortisol level more than 3.15 times the reference range, and shortened activated partial thromboplastin time (aPTT) [<a href="#rid83">83</a>].</p><p>Prophylactic postoperative anticoagulation may reduce the risk of thromboembolic complications. This was illustrated in a retrospective study of 307 patients with Cushing syndrome; postoperative prophylactic anticoagulation with heparin and/or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> appeared to reduce the risk of thromboembolic complications (14 of 232 patients [6 percent]) compared with a historical control group that was not anticoagulated (15 of 75 patients [20 percent]) [<a href="#rid76">76</a>]. Although further studies are needed to confirm its benefit, postoperative anticoagulation prophylaxis seems warranted at present for nonambulatory patients. In the absence of further studies, we would not recommend postoperative anticoagulation in patients who are ambulatory.</p><p>We also encourage our hospitalized patients to get out of bed during the day and to walk for 15 to 20 minutes two or three times a day, if possible.</p><p class="headingAnchor" id="H2344653436"><span class="h3">Other</span><span class="headingEndMark"> — </span>Hypercortisolism may also be associated with heart failure and dilated cardiomyopathy:</p><p class="bulletIndent1"><span class="glyph">●</span>One series reported heart failure in almost one-half of patients older than 40 years [<a href="#rid84">84</a>], but in our experience, it is rare. Dependent edema can also occur, although the mechanism is not well understood. It should not be caused by excess mineralocorticoid activity, due to the phenomenon of aldosterone escape [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dilated cardiomyopathy occurs rarely in Cushing syndrome but it is generally reversible [<a href="#rid86">86</a>]. In one literature review, it was associated with Cushing disease in approximately one-quarter of the patients and with adrenal adenomas in the remainder [<a href="#rid86">86</a>], but it has also been reported in a single patient with ectopic ACTH secretion [<a href="#rid87">87</a>]. It is characterized by cell hypertrophy and myocardial fibrosis [<a href="#rid88">88</a>].</p><p></p><p class="headingAnchor" id="H2778976951"><span class="h2">Bone health/musculoskeletal</span></p><p class="headingAnchor" id="H2476396133"><span class="h3">Proximal muscle wasting and weakness</span><span class="headingEndMark"> — </span>Weakness and proximal muscle wasting are common in Cushing syndrome, being induced by the catabolic effects of excess glucocorticoid on skeletal muscle<strong> </strong> (<a class="graphic graphic_picture graphicRef64072" href="/z/d/graphic/64072.html" rel="external">picture 10</a>). As a result, many patients cannot rise from a squatting position without assistance; patients with more severe disease may be unable to climb stairs or get up from a deep chair. The catabolic effects of cortisol are amplified by physical inactivity [<a href="#rid89">89</a>] (see  <a class="medical medical_review" href="/z/d/html/5171.html" rel="external">"Glucocorticoid-induced myopathy"</a>). In a number of studies, muscle wasting and weakness were uncommon in patients with pseudo-Cushing syndrome [<a href="#rid35">35,49,50,90</a>]. However, in one study of 23 patients with pseudo-Cushing syndrome and 32 with Cushing syndrome, the incidence of weakness was similar in the two groups (approximately 30 percent) [<a href="#rid91">91</a>].</p><p>Hypokalemia, due to decreased renal conversion of cortisol to cortisone by 11-beta hydroxysteroid dehydrogenase type II, allowing for cortisol to exert mineralocorticoid effects, can accentuate the weakness in patients with severe hypercortisolism [<a href="#rid70">70</a>]. On the other hand, a high-protein diet and exercise may improve or mitigate muscle wasting and increase strength.</p><p class="headingAnchor" id="H2151630722"><span class="h3">Bone loss</span><span class="headingEndMark"> — </span>Osteoporosis is common in patients with Cushing syndrome. It is caused by decreased intestinal calcium absorption, decreased bone formation, increased bone resorption, and decreased renal calcium reabsorption [<a href="#rid92">92,93</a>]. It can be demonstrated by densitometry of the lumbar vertebrae, even in young patients. Pathologic fractures may occur, often resulting in severe skeletal pain. (See  <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">"Clinical features and evaluation of glucocorticoid-induced osteoporosis"</a>.)</p><p>The following skeletal abnormalities may be seen:</p><p class="bulletIndent1"><span class="glyph">●</span>A study of 80 patients with Cushing syndrome showed a 76 percent prevalence of osteoporosis [<a href="#rid94">94</a>]. Multiple fractures were more common in patients with ectopic ACTH secretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pathologic rib and long-bone fractures [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteonecrosis (aseptic necrosis) of the femoral heads and rarely the humeral heads, usually only with chronic, high-dose glucocorticoid therapy [<a href="#rid96">96</a>]. Osteonecrosis of the femoral head has been described in few patients with Cushing syndrome [<a href="#rid97">97</a>] and, rarely, it may be the presenting manifestation of Cushing syndrome [<a href="#rid98">98</a>]. (See  <a class="medical medical_review" href="/z/d/html/5613.html" rel="external">"Treatment of nontraumatic hip osteonecrosis (avascular necrosis of the femoral head) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low back pain is very common and is attributed to osteoporosis, vertebral compression, muscle wasting, and the lordotic posture resulting from weight gain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower-extremity insufficiency fractures, particularly of the feet, were reported in 10 women, five of whom had mild disease [<a href="#rid99">99</a>].</p><p></p><p>Increased bone resorption can also lead to hypercalciuria and renal calculi [<a href="#rid100">100</a>]. Hypercalcemia is very rare.</p><p>Bone mineral density improves in adults and children after successful treatment of Cushing syndrome [<a href="#rid22">22,101</a>]. One study of 17 adults found normal bone mineral density in the spine and hip when measured on average at 8.6 years after cure of Cushing syndrome [<a href="#rid102">102</a>]; others have reported normalization within five years in children [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H983737469"><span class="h3">Impact of subclinical hypercortisolism</span><span class="headingEndMark"> — </span>Even patients with mild chronic hypercortisolism, such as women who have adrenal incidentalomas causing slightly increased cortisol secretion but no other clinical manifestations of Cushing syndrome (ie, subclinical Cushing syndrome), may have increased bone turnover, decreased bone mineral density, and vertebral fractures [<a href="#rid104">104</a>]. (See  <a class="medical medical_review" href="/z/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'</a>.)</p><p class="headingAnchor" id="H563140511"><span class="h2">Neuropsychologic changes and cognition</span><span class="headingEndMark"> — </span>A number of neuropsychologic symptoms may occur, including insomnia, depression, and memory loss. Symptoms of psychiatric disease occur in over one-half of patients with Cushing syndrome of any etiology and are, therefore, presumably caused by excess cortisol [<a href="#rid49">49,105,106</a>]. Some patients have psychiatric illness as the presenting symptom [<a href="#rid106">106</a>]. </p><p>Depression occurs in up to 86 percent of patients with Cushing syndrome [<a href="#rid34">34,107,108</a>]. Most have the increased appetite and weight gain that is usually associated with atypical depression [<a href="#rid107">107</a>]. Rarely, however, anorexia and weight loss predominate as is common in melancholic depression [<a href="#rid109">109</a>]. Severely depressed patients may also be suicidal [<a href="#rid49">49,105</a>].</p><p>On the other hand, some patients appear euphoric or manic, particularly early in the course of the illness. Children tend to be overachievers, often ranking near the top of their class [<a href="#rid110">110</a>].</p><p>The most common psychologic symptoms are [<a href="#rid34">34,49,105-107</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Emotional lability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Depression (37 to 86 percent of patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Irritability (86 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety (up to 80 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Panic attacks (up to 30 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild paranoia and mania are less common [<a href="#rid34">34</a>].</p><p></p><p>After correction of the hypercortisolism, resolution of the psychiatric symptoms is variable [<a href="#rid111">111-113</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 33 patients with Cushing syndrome, important psychopathology (predominantly atypical depression) was present in 55 percent before treatment compared with 24 percent one year after successful treatment [<a href="#rid111">111</a>]. There was also a significant improvement in overall mood score. However, important psychopathology developed after treatment in 4 of 17 patients who had no prior psychiatric symptoms, and one of the four became suicidal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other data suggest that Cushing disease has adverse effects on mood and social functioning that persist after surgical cure [<a href="#rid113">113,114</a>]. This was illustrated in a follow-up report of 114 patients with pituitary tumors who had undergone successful pituitary surgery. The 15 patients with treated Cushing disease had significantly worse scores on measures of psychosocial well-being and psychosocial functioning compared with patients with other tumors (nonfunctioning adenomas, macroprolactinomas, acromegaly) in whom the scores were similar [<a href="#rid113">113</a>].</p><p></p><p>In adults, learning, cognition, and memory (especially short-term memory) are impaired by hypercortisolism [<a href="#rid115">115,116</a>]. Bedside assessment of these attributes may be useful in assessing the presence of hypercortisolism [<a href="#rid117">117</a>].</p><p>Hypercortisolism is also associated with a decrease in hippocampal volume and a general reduction in brain volume [<a href="#rid115">115,118</a>]. In one study, the degree of impaired memory was associated with a decrease in hippocampal volume [<a href="#rid119">119</a>]. Brain volume increases but does not always return to normal after cure of the hypercortisolism [<a href="#rid118">118</a>]. </p><p>In patients with Cushing disease in remission, cognitive function may improve but not return to baseline [<a href="#rid120">120,121</a>]. In a study of 24 patients studied before and after treatment, some, but not all, had an improvement in cognitive and memory function [<a href="#rid120">120</a>]. Improvements in the ability to remember a list of unrelated words was associated with an increase in hippocampal volume.</p><p>One study of 11 children found a decline in intelligence quotient (IQ) and cognitive performance at one year after curative surgery, in the absence of psychopathology, despite reversal of cerebral atrophy [<a href="#rid122">122</a>].</p><p class="headingAnchor" id="H316235727"><span class="h2">Infection and immune function</span><span class="headingEndMark"> — </span>Glucocorticoids inhibit immune function, thereby contributing to an increased frequency of infections [<a href="#rid123">123</a>]. In parallel with this, there may be thymic atrophy [<a href="#rid124">124</a>]. Infection accounted for 21.6 percent of deaths in one study of 311 patients with Cushing disease [<a href="#rid125">125</a>]. Nevertheless, opportunistic infections with organisms of low pathogenicity occur only in patients with severe hypercortisolemia, such as those with ectopic ACTH syndrome [<a href="#rid126">126</a>]. In one study, patients with serum cortisol concentrations above 40 mcg/dL (1100 nmol/L), urinary cortisol excretion greater than 2000 mcg/day (5500 nmol/L), or urinary 17-hydroxycorticosteroid (17-OHCS) excretion greater than 35 mg/g creatinine (96 micromol/g creatinine) were likely to have severe infections [<a href="#rid127">127</a>]. Bacterial infections were most common (74 percent), but opportunistic pathogens or both (42.1 and 13.8 percent, respectively) were frequent and should be considered when giving empiric antibiotic coverage to such patients [<a href="#rid127">127</a>].</p><p>The mechanism by which glucocorticoid excess predisposes to infection is poorly understood. One mechanism may be a fall in circulating CD4 cells and decline in natural killer cell activity [<a href="#rid128">128</a>]. Perhaps the major effect is that glucocorticoids inhibit the synthesis of almost all cytokines, apparently by inducing the synthesis of I kappa B alpha, a protein that traps and thereby inactivates nuclear factor kappa B [<a href="#rid129">129,130</a>]. The latter protein is an activator of cytokine genes and mediator of the inflammatory action of tumor necrosis factor.</p><p>Inhibition of cytokine release has another clinically important effect with regard to infection; the associated reduction in inflammatory and febrile responses to bacterial infection may make these infections difficult to detect.</p><p>The increased susceptibility to infection occurs despite a glucocorticoid-induced rise in the circulating neutrophil count. The granulocytosis is partly due to decreased margination and partly to increased circulating granulocyte colony-stimulating factor [<a href="#rid131">131</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Ophthalmologic findings</span><span class="headingEndMark"> — </span>Increased intraocular pressure, cataracts, and central serous chorioretinopathy occur rarely as a result of endogenous Cushing syndrome and are more common with exogenous glucocorticoid administration, in particular, topical steroids [<a href="#rid97">97,132-134</a>].</p><p class="headingAnchor" id="H12296147"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>In spite of advances in diagnosis and treatments for Cushing syndrome, morbidity and mortality rates are still high [<a href="#rid2">2,135-137</a>]. This was best illustrated in a meta-analysis of 14 studies including 3691 patients with Cushing syndrome (13 Cushing disease and 7 adrenal Cushing syndrome) [<a href="#rid136">136</a>]. Overall standardized mortality ratio for all Cushing syndrome was 3.0 (95% CI 2.3-3.9), for Cushing disease 2.8 (95% CI 2.1-3.7), and for adrenal Cushing syndrome 3.3 (95% CI 0.5-6.6). The causes of death were atherosclerotic diseases and thromboembolism (43.4 percent), infection (12.7 percent), malignancy (10.6 percent), active disease (3.5 percent), adrenal insufficiency (3.0 percent), and suicide (2.2 percent). Despite improved outcomes for patients with Cushing syndrome in recent years, increased mortality persists.</p><p class="headingAnchor" id="H439094"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15600.html" rel="external">"Patient education: Cushing syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2173.html" rel="external">"Patient education: Cushing syndrome (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H588676213"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>–<strong> </strong>Estimates of the incidence of Cushing syndrome are imprecise and likely underestimate the incidence of iatrogenic Cushing syndrome, undiagnosed mild hypercortisolism, and the ectopic corticotropin (ACTH) syndrome.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Iatrogenic Cushing syndrome</strong> – More than 10 million Americans receive pharmacologic doses of glucocorticoids each year. Therefore, iatrogenic Cushing syndrome must be more common than any other cause but is seldom reported. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Dermatologic effects and appearance'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cushing disease </strong>– Pituitary ACTH-dependent Cushing disease causes 65 to 70 percent of Cushing syndrome [<a href="#rid1">1</a>]. The reported incidence was 1.2 to 2.4 per million per year in European population-based studies and 6.2 to 7.6 per million person-years in the United States. (See  <a class="medical medical_review" href="/z/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ectopic ACTH syndrome</strong> – Recognized ectopic ACTH syndrome causes 10 to 15 percent of cases. However, its true incidence is probably more common because a number of these patients do not present with catabolic features and are not diagnosed. (See  <a class="medical medical_review" href="/z/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adrenal tumors</strong> – Adrenal carcinoma and adenoma cause a similar number of cases of Cushing syndrome in most series, together comprising approximately 20 percent of all cases. (See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other causes </strong>–<strong> </strong>All other causes of Cushing syndrome are extremely rare, including Cushing syndrome due to either bilateral macronodular adrenal hyperplasia or primary pigmented nodular adrenocortical disease, which are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/148.html" rel="external">"Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia"</a> and  <a class="medical medical_review" href="/z/d/html/152.html" rel="external">"Cushing syndrome due to primary pigmented nodular adrenocortical disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency and severity of symptoms </strong>–<strong> </strong>The presence and relative severity of symptoms varies and are determined by the following factors (see <a class="local">'Frequency and severity of symptoms'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The degree and duration of hypercortisolism.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence or absence of androgen excess (because hypercortisolism alone causes neither hirsutism nor pustular acne).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The cause of the hypercortisolism (because hyperpigmentation is caused by increased secretion of ACTH) and androgen excess occurs only in females with adrenal cancer or ACTH-stimulated hyperandrogenism (the adrenal gland being a major source of androgen production in females but not males). Adrenal adenomas generally lead to isolated hypercortisolism.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adrenal carcinoma or the ectopic ACTH syndrome can cause tumor-related symptoms that may overshadow the effects of hypercortisolism (such as weight loss instead of weight gain).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Most suggestive symptoms </strong>–<strong> </strong>In adults, signs and symptoms most suggestive of the presence of hypercortisolism include proximal muscle weakness, facial plethora, wasting of the extremities with increased fat in the abdomen and face, wide purplish striae, bruising with no obvious trauma, and supraclavicular fat pads. Other symptoms are described above  (<a class="graphic graphic_table graphicRef111525" href="/z/d/graphic/111525.html" rel="external">table 1</a>). (See <a class="local">'Most common symptoms'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An important clinical clue to the presence of glucocorticoid excess is the simultaneous development or accumulation of new features and severity of multiple symptoms consistent with Cushing syndrome. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some of the most common manifestations of Cushing syndrome, such as obesity, hypertension, and glucose intolerance, are less suggestive of the presence of hypercortisolism as they are also common in individuals who do not have adrenal hyperfunction. (See <a class="local">'Frequency and severity of symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excess mortality </strong>–<strong> </strong>In addition to the considerable morbidity caused by hypercortisolism, there is also an increase in mortality rates. (See <a class="local">'Mortality'</a> above.)</p><p></p><p class="headingAnchor" id="H199987406"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Carpenter PC. Diagnostic evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am 1988; 17:445.</a></li><li><a class="nounderline abstract_t">Lindholm J, Juul S, Jørgensen JO, et al. Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001; 86:117.</a></li><li><a class="nounderline abstract_t">Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40:479.</a></li><li><a class="nounderline abstract_t">Broder MS, Neary MP, Chang E, et al. Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients &lt;65 years old in the United States. Pituitary 2015; 18:283.</a></li><li><a class="nounderline abstract_t">Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24:4539.</a></li><li><a class="nounderline abstract_t">Nagy-Mignotte H, Shestaeva O, Vignoud L, et al. Prognostic impact of paraneoplastic cushing's syndrome in small-cell lung cancer. J Thorac Oncol 2014; 9:497.</a></li><li><a class="nounderline abstract_t">Ross NS. Epidemiology of Cushing's syndrome and subclinical disease. Endocrinol Metab Clin North Am 1994; 23:539.</a></li><li><a class="nounderline abstract_t">Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84:440.</a></li><li><a class="nounderline abstract_t">James BC, Aschebrook-Kilfoy B, Cipriani N, et al. The Incidence and Survival of Rare Cancers of the Thyroid, Parathyroid, Adrenal, and Pancreas. Ann Surg Oncol 2016; 23:424.</a></li><li><a class="nounderline abstract_t">Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 1966; 41:572.</a></li><li><a class="nounderline abstract_t">Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322:1195.</a></li><li><a class="nounderline abstract_t">Kasperlik-Załuska AA, Migdalska BM, Zgliczyński S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995; 75:2587.</a></li><li><a class="nounderline abstract_t">Tatsi C, Kamilaris C, Keil M, et al. Paediatric Cushing syndrome: a prospective, multisite, observational cohort study. Lancet Child Adolesc Health 2024; 8:51.</a></li><li><a class="nounderline abstract_t">Magiakou MA, Mastorakos G, Oldfield EH, et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 1994; 331:629.</a></li><li><a class="nounderline abstract_t">Savage MO, Chan LF, Grossman AB, Storr HL. Work-up and management of paediatric Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes 2008; 15:346.</a></li><li><a class="nounderline abstract_t">Batista DL, Oldfield EH, Keil MF, Stratakis CA. Postoperative testing to predict recurrent Cushing disease in children. J Clin Endocrinol Metab 2009; 94:2757.</a></li><li><a class="nounderline abstract_t">Joshi SM, Hewitt RJ, Storr HL, et al. Cushing's disease in children and adolescents: 20 years of experience in a single neurosurgical center. Neurosurgery 2005; 57:281.</a></li><li><a class="nounderline abstract_t">Storr HL, Isidori AM, Monson JP, et al. Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis. J Clin Endocrinol Metab 2004; 89:3818.</a></li><li><a class="nounderline abstract_t">Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981; 71:855.</a></li><li><a class="nounderline abstract_t">Howlett TA, Rees LH, Besser GM. Cushing's syndrome. Clin Endocrinol Metab 1985; 14:911.</a></li><li><a class="nounderline abstract_t">Katayama M, Nomura K, Ujihara M, et al. Age-dependent decline in cortisol levels and clinical manifestations in patients with ACTH-independent Cushing's syndrome. Clin Endocrinol (Oxf) 1998; 49:311.</a></li><li><a class="nounderline abstract_t">Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002; 87:998.</a></li><li><a class="nounderline abstract_t">Ross EJ, Linch DC. Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2:646.</a></li><li><a class="nounderline abstract_t">Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526.</a></li><li><a class="nounderline abstract_t">Nieman LK. Cushing's syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol 2015; 173:M33.</a></li><li><a class="nounderline abstract_t">Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 1998; 83:3083.</a></li><li><a class="nounderline abstract_t">Penezić Z, Zarković M, Vujović S, et al. Gonadotropin pulsatility in Cushing's syndrome compared with polycystic ovary syndrome. Gynecol Endocrinol 2005; 20:150.</a></li><li><a class="nounderline abstract_t">Kaltsas GA, Korbonits M, Isidori AM, et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome? Clin Endocrinol (Oxf) 2000; 53:493.</a></li><li><a class="nounderline abstract_t">Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 1974; 39:340.</a></li><li><a class="nounderline abstract_t">Hammond GL, Ruokonen A, Kontturi M, et al. The simultaneous radioimmunoassay of seven steroids in human spermatic and peripheral venous blood. J Clin Endocrinol Metab 1977; 45:16.</a></li><li><a class="nounderline abstract_t">Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240:324.</a></li><li><a class="nounderline abstract_t">D'Agata R, Malozowski S, Barkan A, et al. Steroid biosynthesis in human adrenal tumors. Horm Metab Res 1987; 19:386.</a></li><li><a class="nounderline abstract_t">Gröndal S, Eriksson B, Hagenäs L, et al. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol (Copenh) 1990; 122:656.</a></li><li><a class="nounderline abstract_t">Starkman MN. Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol Metab Clin North Am 2013; 42:477.</a></li><li><a class="nounderline abstract_t">Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19:647.</a></li><li><a class="nounderline abstract_t">Rosenberg EM, Hahn TJ, Orth DN, et al. ACTH-secreting medullary carcinoma of the thyroid presenting a severe idiopathic osteoporosis and senile purpura: report of a case and review of the literature. J Clin Endocrinol Metab 1978; 47:255.</a></li><li><a class="nounderline abstract_t">Urbanic RC, George JM. Cushing's disease--18 years' experience. Medicine (Baltimore) 1981; 60:14.</a></li><li><a class="nounderline abstract_t">Ferguson JK, Donald RA, Weston TS, Espiner EA. Skin thickness in patients with acromegaly and Cushing's syndrome and response to treatment. Clin Endocrinol (Oxf) 1983; 18:347.</a></li><li><a class="nounderline abstract_t">Mountjoy KG. The human melanocyte stimulating hormone receptor has evolved to become "super-sensitive" to melanocortin peptides. Mol Cell Endocrinol 1994; 102:R7.</a></li><li><a class="nounderline abstract_t">Giordano C, Guarnotta V, Pivonello R, et al. Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? Eur J Endocrinol 2014; 170:311.</a></li><li><a class="nounderline abstract_t">Leibowitz G, Tsur A, Chayen SD, et al. Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf) 1996; 44:717.</a></li><li><a class="nounderline abstract_t">Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab 2003; 88:5808.</a></li><li><a class="nounderline abstract_t">Mullan K, Black N, Thiraviaraj A, et al. Is there value in routine screening for Cushing's syndrome in patients with diabetes? J Clin Endocrinol Metab 2010; 95:2262.</a></li><li><a class="nounderline abstract_t">Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 2010; 95:2736.</a></li><li><a class="nounderline abstract_t">Koh JM, Kim JY, Chung YE, et al. Increased urinary albumin excretion in Cushing's syndrome: remission after correction of hypercortisolaemia. Clin Endocrinol (Oxf) 2000; 52:349.</a></li><li><a class="nounderline abstract_t">Wajchenberg BL, Bosco A, Marone MM, et al. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab 1995; 80:2791.</a></li><li><a class="nounderline abstract_t">Koch CA, Doppman JL, Watson JC, et al. Spinal epidural lipomatosis in a patient with the ectopic corticotropin syndrome. N Engl J Med 1999; 341:1399.</a></li><li><a class="nounderline abstract_t">Davies JH, Storr HL, Davies K, et al. Final adult height and body mass index after cure of paediatric Cushing's disease. Clin Endocrinol (Oxf) 2005; 62:466.</a></li><li><a class="nounderline abstract_t">PLOTZ CM, KNOWLTON AI, RAGAN C. The natural history of Cushing's syndrome. Am J Med 1952; 13:597.</a></li><li><a class="nounderline abstract_t">Panzer SW, Patrinely JR, Wilson HK. Exophthalmos and iatrogenic Cushing's syndrome. Ophthal Plast Reconstr Surg 1994; 10:278.</a></li><li><a class="nounderline abstract_t">Bodelier AG, Groeneveld W, van der Linden AN, Haak HR. Symptomatic epidural lipomatosis in ectopic Cushing's syndrome. Eur J Endocrinol 2004; 151:765.</a></li><li><a class="nounderline abstract_t">Kola B, Christ-Crain M, Lolli F, et al. Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab 2008; 93:4969.</a></li><li><a class="nounderline abstract_t">Tomlinson JW, Draper N, Mackie J, et al. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab 2002; 87:57.</a></li><li><a class="nounderline abstract_t">Weise M, Abad V, Considine RV, et al. Leptin secretion in Cushing's syndrome: preservation of diurnal rhythm and absent response to corticotropin-releasing hormone. J Clin Endocrinol Metab 1999; 84:2075.</a></li><li><a class="nounderline abstract_t">Schafroth U, Godang K, Ueland T, et al. Leptin levels in relation to body composition and insulin concentration in patients with endogenous Cushing's syndrome compared to controls matched for body mass index. J Endocrinol Invest 2000; 23:349.</a></li><li><a class="nounderline abstract_t">Shipley JE, Schteingart DE, Tandon R, Starkman MN. Sleep architecture and sleep apnea in patients with Cushing's disease. Sleep 1992; 15:514.</a></li><li><a class="nounderline abstract_t">Rosenow F, McCarthy V, Caruso AC. Sleep apnoea in endocrine diseases. J Sleep Res 1998; 7:3.</a></li><li><a class="nounderline abstract_t">Neary NM, Booker OJ, Abel BS, et al. Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. J Clin Endocrinol Metab 2013; 98:2045.</a></li><li><a class="nounderline abstract_t">Mancini T, Kola B, Mantero F, et al. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004; 61:768.</a></li><li><a class="nounderline abstract_t">Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84:2664.</a></li><li><a class="nounderline abstract_t">Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88:2527.</a></li><li><a class="nounderline abstract_t">Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002; 87:4872.</a></li><li><a class="nounderline abstract_t">Debono M, Bradburn M, Bull M, et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 2014; 99:4462.</a></li><li><a class="nounderline abstract_t">Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2014; 2:396.</a></li><li><a class="nounderline abstract_t">Whitworth JA. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int Suppl 1992; 37:S34.</a></li><li><a class="nounderline abstract_t">Saruta T, Suzuki H, Handa M, et al. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986; 62:275.</a></li><li><a class="nounderline abstract_t">Pirpiris M, Sudhir K, Yeung S, et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19:567.</a></li><li><a class="nounderline abstract_t">Isidori AM, Graziadio C, Paragliola RM, et al. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens 2015; 33:44.</a></li><li><a class="nounderline abstract_t">Ulick S, Wang JZ, Blumenfeld JD, Pickering TG. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1992; 74:963.</a></li><li><a class="nounderline abstract_t">Stewart PM, Walker BR, Holder G, et al. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1995; 80:3617.</a></li><li><a class="nounderline abstract_t">Takagi S, Tanabe A, Tsuiki M, et al. Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal Cushing's syndrome. Endocr J 2009; 56:1009.</a></li><li><a class="nounderline abstract_t">Jha S, Sinaii N, McGlotten RN, Nieman LK. Remission of hypertension after surgical cure of Cushing's syndrome. Clin Endocrinol (Oxf) 2020; 92:124.</a></li><li><a class="nounderline abstract_t">Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2002; 970:134.</a></li><li><a class="nounderline abstract_t">CHRISTY NP, LARAGH JH. Pathogenesis of hypokalemic alkalosis in Cushing's syndrome. N Engl J Med 1961; 265:1083.</a></li><li><a class="nounderline abstract_t">Sjöberg HE, Blombäck M, Granberg PO. Thromboembolic complications, heparin treatment in increase in coagulation factors in Cushing's syndrome. Acta Med Scand 1976; 199:95.</a></li><li><a class="nounderline abstract_t">Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002; 87:3662.</a></li><li><a class="nounderline abstract_t">van der Pas R, Leebeek FW, Hofland LJ, et al. Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 2013; 78:481.</a></li><li><a class="nounderline abstract_t">Isidori AM, Minnetti M, Sbardella E, et al. Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol 2015; 173:R101.</a></li><li><a class="nounderline abstract_t">Van Zaane B, Nur E, Squizzato A, et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 2009; 94:2743.</a></li><li><a class="nounderline abstract_t">Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5:692.</a></li><li><a class="nounderline abstract_t">Stuijver DJ, van Zaane B, Feelders RA, et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab 2011; 96:3525.</a></li><li><a class="nounderline abstract_t">Terzolo M, Allasino B, Bosio S, et al. Hyperhomocysteinemia in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:3745.</a></li><li><a class="nounderline abstract_t">Zilio M, Mazzai L, Sartori MT, et al. A venous thromboembolism risk assessment model for patients with Cushing's syndrome. Endocrine 2016; 52:322.</a></li><li><a class="nounderline abstract_t">Ross EJ, Marshall-Jones P, Friedman M. Cushing's syndrome: diagnostic criteria. Q J Med 1966; 35:149.</a></li><li><a class="nounderline abstract_t">Gonzalez-Campoy JM, Romero JC, Knox FG. Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems. Kidney Int 1989; 35:767.</a></li><li><a class="nounderline abstract_t">Marchand L, Segrestin B, Lapoirie M, et al. Dilated Cardiomyopathy Revealing Cushing Disease: A Case Report and Literature Review. Medicine (Baltimore) 2015; 94:e2011.</a></li><li><a class="nounderline abstract_t">Pingle SR, Shah T, Mosleh W, Kim AS. Cushing syndrome cardiomyopathy: an unusual manifestation of small-cell lung cancer. ESC Heart Fail 2020; 7:3189.</a></li><li><a class="nounderline abstract_t">Frustaci A, Letizia C, Verardo R, et al. Atrogin-1 Pathway Activation in Cushing Syndrome Cardiomyopathy. J Am Coll Cardiol 2016; 67:116.</a></li><li><a class="nounderline abstract_t">Ferrando AA, Stuart CA, Sheffield-Moore M, Wolfe RR. Inactivity amplifies the catabolic response of skeletal muscle to cortisol. J Clin Endocrinol Metab 1999; 84:3515.</a></li><li><a class="nounderline abstract_t">Alwani RA, Schmit Jongbloed LW, de Jong FH, et al. Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests. Eur J Endocrinol 2014; 170:477.</a></li><li><a class="nounderline abstract_t">Pecori Giraldi F, Pivonello R, Ambrogio AG, et al. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) 2007; 66:251.</a></li><li><a class="nounderline abstract_t">Adler RA, Rosen CJ. Glucocorticoids and osteoporosis. Endocrinol Metab Clin North Am 1994; 23:641.</a></li><li><a class="nounderline abstract_t">Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112:352.</a></li><li><a class="nounderline abstract_t">Tauchmanovà L, Pivonello R, Di Somma C, et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 2006; 91:1779.</a></li><li><a class="nounderline abstract_t">Kaplan FS, Leone VJ, Fallon MD, et al. Multiple pathologic fractures of the appendicular skeleton in a patient with Cushing's disease. Clin Orthop Relat Res 1987; :171.</a></li><li><a class="nounderline abstract_t">Felson DT, Anderson JJ. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet 1987; 1:902.</a></li><li><a class="nounderline abstract_t">Pazderska A, Crowther S, Govender P, et al. Spontaneous resolution of avascular necrosis of femoral heads following cure of Cushing's syndrome. Endocrinol Diabetes Metab Case Rep 2016; 2016:160015.</a></li><li><a class="nounderline abstract_t">Koch CA, Tsigos C, Patronas NJ, Papanicolaou DA. Cushing's disease presenting with avascular necrosis of the hip: an orthopedic emergency. J Clin Endocrinol Metab 1999; 84:3010.</a></li><li><a class="nounderline abstract_t">Poonuru S, Findling JW, Shaker JL. Lower extremity insufficiency fractures: an underappreciated manifestation of endogenous Cushing's syndrome. Osteoporos Int 2016; 27:3645.</a></li><li><a class="nounderline abstract_t">LAAKE H. The action of corticosteroids on the renal reabsorption of calcium. Acta Endocrinol (Copenh) 1960; 34:60.</a></li><li><a class="nounderline abstract_t">Kristo C, Jemtland R, Ueland T, et al. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol 2006; 154:109.</a></li><li><a class="nounderline abstract_t">Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf) 1992; 36:229.</a></li><li><a class="nounderline abstract_t">Tóth M, Grossman A. Glucocorticoid-induced osteoporosis: lessons from Cushing's syndrome. Clin Endocrinol (Oxf) 2013; 79:1.</a></li><li><a class="nounderline abstract_t">Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J Bone Miner Res 2011; 26:1816.</a></li><li><a class="nounderline abstract_t">Haskett RF. Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry 1985; 142:911.</a></li><li><a class="nounderline abstract_t">Kelly WF. Psychiatric aspects of Cushing's syndrome. QJM 1996; 89:543.</a></li><li><a class="nounderline abstract_t">Loosen PT, Chambliss B, DeBold CR, et al. Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry 1992; 25:192.</a></li><li><a class="nounderline abstract_t">Dorn LD, Burgess ES, Dubbert B, et al. Psychopathology in patients with endogenous Cushing's syndrome: 'atypical' or melancholic features. Clin Endocrinol (Oxf) 1995; 43:433.</a></li><li><a class="nounderline abstract_t">BLACK MM, HALL R, KAY DW, KILBORN JR. ANOREXIA NERVOSA IN CUSHING'S SYNDROME. J Clin Endocrinol Metab 1965; 25:1030.</a></li><li><a class="nounderline abstract_t">Devoe DJ, Miller WL, Conte FA, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997; 82:3196.</a></li><li><a class="nounderline abstract_t">Dorn LD, Burgess ES, Friedman TC, et al. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997; 82:912.</a></li><li><a class="nounderline abstract_t">Kelly WF, Kelly MJ, Faragher B. A prospective study of psychiatric and psychological aspects of Cushing's syndrome. Clin Endocrinol (Oxf) 1996; 45:715.</a></li><li><a class="nounderline abstract_t">Heald AH, Ghosh S, Bray S, et al. Long-term negative impact on quality of life in patients with successfully treated Cushing's disease. Clin Endocrinol (Oxf) 2004; 61:458.</a></li><li><a class="nounderline abstract_t">Tiemensma J, Biermasz NR, Middelkoop HA, et al. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease. J Clin Endocrinol Metab 2010; 95:E129.</a></li><li><a class="nounderline abstract_t">Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol Psychiatry 1992; 32:756.</a></li><li><a class="nounderline abstract_t">Forget H, Lacroix A, Somma M, Cohen H. Cognitive decline in patients with Cushing's syndrome. J Int Neuropsychol Soc 2000; 6:20.</a></li><li><a class="nounderline abstract_t">Starkman MN, Schteingart DE, Schork MA. Correlation of bedside cognitive and neuropsychological tests in patients with Cushing's syndrome. Psychosomatics 1986; 27:508.</a></li><li><a class="nounderline abstract_t">Bourdeau I, Bard C, Noël B, et al. Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 2002; 87:1949.</a></li><li><a class="nounderline abstract_t">Resmini E, Santos A, Gómez-Anson B, et al. Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:663.</a></li><li><a class="nounderline abstract_t">Starkman MN, Giordani B, Gebarski SS, Schteingart DE. Improvement in learning associated with increase in hippocampal formation volume. Biol Psychiatry 2003; 53:233.</a></li><li><a class="nounderline abstract_t">Tiemensma J, Kokshoorn NE, Biermasz NR, et al. Subtle cognitive impairments in patients with long-term cure of Cushing's disease. J Clin Endocrinol Metab 2010; 95:2699.</a></li><li><a class="nounderline abstract_t">Merke DP, Giedd JN, Keil MF, et al. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin Endocrinol Metab 2005; 90:2531.</a></li><li><a class="nounderline abstract_t">Dekkers OM, Horváth-Puhó E, Jørgensen JO, et al. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J Clin Endocrinol Metab 2013; 98:2277.</a></li><li><a class="nounderline abstract_t">Hanson JA, Sohaib SA, Newell-Price J, et al. Computed tomography appearance of the thymus and anterior mediastinum in active Cushing's syndrome. J Clin Endocrinol Metab 1999; 84:602.</a></li><li><a class="nounderline abstract_t">Ntali G, Asimakopoulou A, Siamatras T, et al. Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 2013; 169:715.</a></li><li><a class="nounderline abstract_t">Graham BS, Tucker WS Jr. Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med 1984; 101:334.</a></li><li><a class="nounderline abstract_t">Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 2000; 85:42.</a></li><li><a class="nounderline abstract_t">Kronfol Z, Starkman M, Schteingart DE, et al. Immune regulation in Cushing's syndrome: relationship to hypothalamic-pituitary-adrenal axis hormones. Psychoneuroendocrinology 1996; 21:599.</a></li><li><a class="nounderline abstract_t">Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283.</a></li><li><a class="nounderline abstract_t">Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270:286.</a></li><li><a class="nounderline abstract_t">Jilma B, Stohlawetz P, Pernerstorfer T, et al. Glucocorticoids dose-dependently increase plasma levels of granulocyte colony stimulating factor in man. J Clin Endocrinol Metab 1998; 83:1037.</a></li><li><a class="nounderline abstract_t">Khaw KW, Jalaludin MY, Suhaimi H, et al. Endogenous Cushing syndrome from an ectopic adrenocorticotropic hormone production as a rare cause of ocular hypertension. J AAPOS 2010; 14:356.</a></li><li><a class="nounderline abstract_t">Huschle OK, Jonas JB, Koniszewski G, et al. [Glaucoma in central hypothalamic-hypophyseal Cushing syndrome]. Fortschr Ophthalmol 1990; 87:453.</a></li><li><a class="nounderline abstract_t">Jonas JB, Huschle O, Koniszewski G, et al. Intraocular pressure in patients with Cushing's disease. Graefes Arch Clin Exp Ophthalmol 1990; 228:407.</a></li><li><a class="nounderline abstract_t">Clayton RN, Jones PW, Reulen RC, et al. Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 2016; 4:569.</a></li><li><a class="nounderline abstract_t">Limumpornpetch P, Morgan AW, Tiganescu A, et al. The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality. J Clin Endocrinol Metab 2022; 107:2377.</a></li><li><a class="nounderline abstract_t">Graversen D, Vestergaard P, Stochholm K, et al. Mortality in Cushing's syndrome: a systematic review and meta-analysis. Eur J Intern Med 2012; 23:278.</a></li></ol></div><div id="topicVersionRevision">Topic 143 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3065076" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnostic evaluation of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231987" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence and late prognosis of cushing's syndrome: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8187313" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Morbidity and mortality in Cushing's disease: an epidemiological approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24803324" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients&lt;65 years old in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008692" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24736072" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prognostic impact of paraneoplastic cushing's syndrome in small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7805652" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of Cushing's syndrome and subclinical disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022398" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26467460" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Incidence and Survival of Rare Cancers of the Thyroid, Parathyroid, Adrenal, and Pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5923598" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Adrenal cortical carcinoma. Clinical features of 138 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2325710" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7736405" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38097317" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Paediatric Cushing syndrome: a prospective, multisite, observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8052272" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594275" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Work-up and management of paediatric Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470618" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Postoperative testing to predict recurrent Cushing disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16094156" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cushing's disease in children and adolescents: 20 years of experience in a single neurosurgical center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292311" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6272575" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3002679" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9861321" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Age-dependent decline in cortisol levels and clinical manifestations in patients with ACTH-independent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889151" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adrenal incidentaloma: a new cause of the metabolic syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6125785" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334580" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26156970" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cushing's syndrome: update on signs, symptoms and biochemical screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9745407" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16019354" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gonadotropin pulsatility in Cushing's syndrome compared with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11012575" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4278727" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/874062" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The simultaneous radioimmunoassay of seven steroids in human spermatic and peripheral venous blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3353726" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Molecular cloning of human and rat complementary DNA encoding androgen receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3499371" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Steroid biosynthesis in human adrenal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2141212" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011881" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9793762" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/233664" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : ACTH-secreting medullary carcinoma of the thyroid presenting a severe idiopathic osteoporosis and senile purpura: report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7453562" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cushing's disease--18 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6872269" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Skin thickness in patients with acromegaly and Cushing's syndrome and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7926261" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The human melanocyte stimulating hormone receptor has evolved to become "super-sensitive" to melanocortin peptides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24255133" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759185" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671173" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Occult Cushing's syndrome in type-2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20237165" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Is there value in routine screening for Cushing's syndrome in patients with diabetes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375210" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10718833" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Increased urinary albumin excretion in Cushing's syndrome: remission after correction of hypercortisolaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7673425" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10577094" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Spinal epidural lipomatosis in a patient with the ectopic corticotropin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15807878" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Final adult height and body mass index after cure of paediatric Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12996538" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The natural history of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7865451" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Exophthalmos and iatrogenic Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15588244" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Symptomatic epidural lipomatosis in ectopic Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18782871" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788623" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372713" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Leptin secretion in Cushing's syndrome: preservation of diurnal rhythm and absent response to corticotropin-releasing hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10908161" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Leptin levels in relation to body composition and insulin concentration in patients with endogenous Cushing's syndrome compared to controls matched for body mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1335612" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sleep architecture and sleep apnea in patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9613423" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sleep apnoea in endocrine diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23559084" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579193" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443657" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788849" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12414841" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25238207" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24795253" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1321309" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Adrenocorticotrophin and steroid-induced hypertension in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510223" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1592452" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pressor responsiveness in corticosteroid-induced hypertension in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415766" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1569172" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8530609" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789419" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31721265" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Remission of hypertension after surgical cure of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12381548" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13879332" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pathogenesis of hypokalemic alkalosis in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1251777" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Thromboembolic complications, heparin treatment in increase in coagulation factors in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161492" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23134530" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25987566" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19454584" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hypercoagulable state in Cushing's syndrome: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17367492" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Incidence and mortality of venous thrombosis: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880802" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292300" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hyperhomocysteinemia in patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26113424" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A venous thromboembolism risk assessment model for patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5912055" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cushing's syndrome: diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2523495" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26579807" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Dilated Cardiomyopathy Revealing Cushing Disease: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32573943" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cushing syndrome cardiomyopathy: an unusual manifestation of small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26764074" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Atrogin-1 Pathway Activation in Cushing Syndrome Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522988" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Inactivity amplifies the catabolic response of skeletal muscle to cortisol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24394725" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223996" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7805660" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Glucocorticoids and osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2407167" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Glucocorticoid-induced osteoporosis: pathogenesis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16522701" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3815944" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Multiple pathologic fractures of the appendicular skeleton in a patient with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2882300" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27252864" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Spontaneous resolution of avascular necrosis of femoral heads following cure of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487656" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cushing's disease presenting with avascular necrosis of the hip: an orthopedic emergency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27525744" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Lower extremity insufficiency fractures: an underappreciated manifestation of endogenous Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14413155" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The action of corticosteroids on the renal reabsorption of calcium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16381999" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1563076" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Normal bone mineral density following cure of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23452135" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Glucocorticoid-induced osteoporosis: lessons from Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21472775" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2992298" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Diagnostic categorization of psychiatric disturbance in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759496" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Psychiatric aspects of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1528959" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Psychiatric phenomenology in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586617" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Psychopathology in patients with endogenous Cushing's syndrome: 'atypical' or melancholic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14328373" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : ANOREXIA NERVOSA IN CUSHING'S SYNDROME.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329338" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062506" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039337" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A prospective study of psychiatric and psychological aspects of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15473878" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Long-term negative impact on quality of life in patients with successfully treated Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660031" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1450290" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10761364" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Cognitive decline in patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3737840" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Correlation of bedside cognitive and neuropsychological tests in patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11994323" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22162471" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12559656" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Improvement in learning associated with increase in hippocampal formation volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371667" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Subtle cognitive impairments in patients with long-term cure of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741254" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23533241" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Multisystem morbidity and mortality in Cushing's syndrome: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022423" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Computed tomography appearance of the thymus and anterior mediastinum in active Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23996696" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6331781" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Opportunistic infections in endogenous Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634361" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9044443" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Immune regulation in Cushing's syndrome: relationship to hypothalamic-pituitary-adrenal axis hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7569975" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7569976" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9506771" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Glucocorticoids dose-dependently increase plasma levels of granulocyte colony stimulating factor in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20637667" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Endogenous Cushing syndrome from an ectopic adrenocorticotropic hormone production as a rare cause of ocular hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2177029" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : [Glaucoma in central hypothalamic-hypophyseal Cushing syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2227481" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Intraocular pressure in patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265184" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35486378" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22385888" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Mortality in Cushing's syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
